-
公开(公告)号:US20240336572A1
公开(公告)日:2024-10-10
申请号:US18626467
申请日:2024-04-04
Applicant: Pfizer Inc.
Inventor: Samit Kumar Bhattacharya , Edward Lee Conn , David Christopher Ebner , Brian Stephen Gerstenberger , Chan Woo Huh , Daniel Wei-Shung Kung , Alan Martin Mathiowetz , Jessica Gloria Katherine O'Brien , Meihua Mike Tu , Kimberly O'Keefe Cameron , Dilinie Prasadhini Fernando , Kevin James Filipski , Esther Cheng Yin Lee , Sarah Jane Mear , Aaron Christopher Smith
IPC: C07D231/56 , A61K31/416
CPC classification number: C07D231/56 , A61K31/416
Abstract: The invention relates to substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to pharmaceutical compositions comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof and at least one pharmaceutically acceptable excipient, and methods of treating a condition comprising administering AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.
-
公开(公告)号:US10975065B2
公开(公告)日:2021-04-13
申请号:US16576997
申请日:2019-09-20
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, Jr. , Mark Edward Schnute , Daniel Wei-Shung Kung , Daniel Copley Schmitt , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , A61P29/00 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07F9/6558
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
3.
公开(公告)号:US20200095239A1
公开(公告)日:2020-03-26
申请号:US16576997
申请日:2019-09-20
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Christopher Flick , Vincent Michael Lombardo , James John Mousseau , Philippe Marcel Nuhant , Ralph Pelton Robinson, JR. , Mark Edward Schnute , Daniel Wei-Shung Kung , Daniel Copley Schmitt , Atli Thorarensen , John Isidro Trujillo , Rayomand Jal Unwalla , Huixian Wu
IPC: C07D413/14 , C07D401/12 , C07D401/14 , C07D417/12 , C07D413/12 , C07D405/14 , C07D417/14 , C07F9/6558 , A61P29/00
Abstract: The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.
-
公开(公告)号:US20160304469A1
公开(公告)日:2016-10-20
申请号:US15191943
申请日:2016-06-24
Applicant: Pfizer Inc.
Inventor: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K45/06 , C07D401/04 , C07D405/04 , C07D403/04 , C07D471/04 , C07D409/04 , C07D417/04 , C07D405/10 , C07D405/06 , C07D403/06 , C07D403/10 , C07D401/06 , C07D413/06 , A61K31/5377 , C07D403/12 , A61K31/513
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号:US09440949B2
公开(公告)日:2016-09-13
申请号:US14643210
申请日:2015-03-10
Applicant: PFIZER INC.
Inventor: Shawn Cabral , Kentaro Futatsugi , David Hepworth , Kim Huard , Daniel Wei-Shung Kung , Suvi Tuula Marjukka Orr , Kun Song
IPC: A61K31/5377 , A61K31/606 , A61K31/506 , A61K31/4545 , A61K45/06 , C07D401/04 , C07D487/04 , C07D413/14 , C07D491/08 , C07D401/14 , C07D487/02
CPC classification number: A61K31/506 , A61K31/4545 , A61K31/5377 , A61K31/606 , A61K45/06 , C07D401/04 , C07D401/14 , C07D413/14 , C07D487/02 , C07D487/04 , C07D491/08
Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Abstract translation: 本文描述了抑制二酰基甘油酰基转移酶2(DGAT2)的活性的式I化合物及其在治疗与动物相关疾病中的用途。
-
公开(公告)号:US20160016940A1
公开(公告)日:2016-01-21
申请号:US14773954
申请日:2013-09-24
Applicant: PFIZER INC.
Inventor: Samit Kumar Bhattacharya , Kimberly O'Keefe Cameron , Matthew Scott Dowling , David Christopher Ebner , David James Edmonds , Dilinie Prasadhini Fernando , Kevin James Filipski , Daniel Wei-Shung Kung , Esther Cheng Yin Lee , Aaron Christopher Smith , Meihua Mike Tu
IPC: C07D405/12 , C07D401/12 , C07D403/12 , C07D401/04
CPC classification number: C07D405/12 , A61K31/4439 , C07D401/04 , C07D401/12 , C07D403/12
Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶(AMPK)的式(I)的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病,病症或障碍的方法。
-
公开(公告)号:US20140288049A1
公开(公告)日:2014-09-25
申请号:US14299497
申请日:2014-06-09
Applicant: Pfizer Inc.
Inventor: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , C07D401/04 , C07D405/04 , C07D403/04 , C07D471/04 , A61K31/5377 , C07D417/04 , C07D403/06 , C07D403/10 , C07D401/06 , C07D413/06 , A61K31/513 , C07D409/04
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
公开(公告)号:US08507681B2
公开(公告)日:2013-08-13
申请号:US13644415
申请日:2012-10-04
Applicant: Pfizer Inc.
Inventor: Scott William Bagley , David Andrew Griffith , Daniel Wei-Shung Kung
IPC: C07D401/04 , C07D401/14 , A61K31/438
CPC classification number: C07D471/10 , C07D519/00
Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
-
公开(公告)号:US20240124450A1
公开(公告)日:2024-04-18
申请号:US18466034
申请日:2023-09-13
Applicant: Pfizer Inc.
Inventor: Andrea Nicole Bootsma , David Christopher Ebner , Daniel Wei-Shung Kung , Matthew Alexander Perry , Daniel Copley Schmitt , Joseph Walter Strohbach , Atli Thorarensen
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: A compound of formula I having the structure:
or a pharmaceutically acceptable salt thereof, wherein A1 and A2 are independently O or S; X is selected from CH2, CD2, NR3, O, and S, where R3 is selected from hydrogen, C1-C4 linear or branched chain alkyl, halo(C1-C4)linear or branched chain alkyl, and hydroxyl(C1-C4)linear or branched chain alkyl; Y and Z are selected from C and N, where when Y is C, then Z is N, and when Y is N, then Z is C; R1 and R2 are independently selected from hydrogen, deuterium, C1-C4 linear or branched chain alkyl, etc.; or a C1-C2 alkyl substituted with a C3-C5 cycloalkyl ring; or taken together to form a C3-C6 cycloalkyl ring; or where X is CH2 or CD2, then R1 and R2 are independently selected from hydrogen, deuterium, halogen, hydroxyl, C1-C4 linear or branched chain alkyl, etc.; R4 is selected from hydrogen, deuterium, cyano, halogen, (C1-C3) alkoxy, etc.; R5 is selected from hydrogen, deuterium, halogen, C1-C3 alkoxy, amino, (C1-C4 linear or branched chain alkyl)amino, etc.; R6 is selected from hydrogen, deuterium, halogen, CO2R7 where R7 is selected from H and C1-C4 linear or branched chain alkyl, etc.; R8 is selected from hydrogen, deuterium, and C1-C3 linear or branched chain alkyl; R9 is selected from C1-C3 linear or branched chain alkyl, and a halo(C1-C3)linear or branched chain alkyl; and, n and m are independently selected from 0, 1 and 2. The invention also relates to pharmaceutical compositions thereof and therapeutic methods of use therewith.-
公开(公告)号:US09873673B2
公开(公告)日:2018-01-23
申请号:US15191943
申请日:2016-06-24
Applicant: Pfizer Inc.
Inventor: Philip A. Carpino , Edward L. Conn , Robert L. Dow , Matthew S. Dowling , David Hepworth , Daniel Wei-Shung Kung , Suvi Orr , Benjamin N. Rocke , Roger B. Ruggeri , Matthew F. Sammons , Joseph S. Warmus , Yan Zhang
IPC: C07D239/56 , A61K31/513 , A61K31/352 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/10 , C07D487/04 , C07D417/04 , C07D471/04 , A61K31/37 , C07D405/06
CPC classification number: C07D239/56 , A61K31/352 , A61K31/37 , A61K31/513 , A61K31/5377 , A61K45/06 , C07D401/04 , C07D401/06 , C07D401/10 , C07D403/04 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/10 , C07D409/04 , C07D409/10 , C07D413/06 , C07D417/04 , C07D417/10 , C07D471/04 , C07D487/04 , A61K2300/00
Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
-
-
-
-
-
-
-
-
-